Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma

109

Citations

45

References

2004

Year

Andrew Davies, A. Z. S. Rohatiner, Stephen Howell, K. E. Britton, S. E. Owens, Ivana N. Micallef, D.P. Deakin, BM Carrington, Jeremy Lawrance, Sarah Vinnicombe,

Journal of Clinical Oncology

Abstract

High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed.

References

	Year	Citations

Page 1